The -1131 T > C and S19W APOA5 gene polymorphisms are associated with high levels of triglycerides and apolipoprotein C-III, but not with coronary artery disease: an angiographic study

Atherosclerosis

Volumn 191, Issue 2, 2007, Pages 409-417

  Martinelli, Nicola ^a   Trabetti, Elisabetta ^a   Bassi, Antonella ^a   Girelli, Domenico ^a   Friso, Simonetta ^a   Pizzolo, Francesca ^a   Sandri, Marco ^a   Malerba, Giovanni ^a   Pignatti, Pier Franco ^a   Corrocher, Roberto ^a   Olivieri, Oliviero ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

APOA5 polymorphisms; Apolipoprotein C III; Coronary artery disease; Triglycerides

Indexed keywords

APOLIPOPROTEIN C; TRIACYLGLYCEROL;

ADULT; AGED; ALLELE; ANGIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; GENE IDENTIFICATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; MOLECULAR MODEL; MULTIPLE LINEAR REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; STANDARDIZATION;

ADULT; AGED; APOLIPOPROTEIN C-III; APOLIPOPROTEINS A; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CYTOSINE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPERTRIGLYCERIDEMIA; LINEAR MODELS; MALE; MIDDLE AGED; ODDS RATIO; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT; RISK FACTORS; SERINE; THYMINE; TRIGLYCERIDES; TRYPTOPHAN;

EID: 33947146635     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.04.009     Document Type: Article

References (30)

1. Ginsberg H.N. Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy. Am J Cardiol 87 (2001) 1174-1180
2. Perusse L., Rice T., Despres J.P., et al. Familial resemblance of plasma lipids, lipoproteins and postheparin lipoprotein and hepatic lipases in the HERITAGE family study. Arterioscler Thromb Vasc Biol 17 (1997) 3263-3269
3. van Dijk K.W., Rensen P.C., Voshol P.J., and Havekes L.M. The role and mode of action of apolipoproteins C-III and AV: synergistic actors in triglyceride metabolism?. Curr Opin Lipidol 15 (2004) 239-246
4. Pennacchio L.A., Olivier M., Hubacek J.A., et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294 (2001) 169-173
5. van der Vliet H.N., Sammels M.G., Leegwater A.C., et al. Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J Biol Chem 276 (2001) 44512-44520
6. O'Brien P.J., Alborn W.E., Sloan J.H., et al. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin Chem 51 (2005) 351-359
7. Oliva C.P., Pisciotta L., Li Volti G., et al. Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler Thromb Vasc Biol 25 (2005) 411-417
8. Marcais C., Verges B., Charriere S., et al. APOA5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J Clin Invest 115 (2005) 2862-2869
9. Merkel M., and Heeren J. Give me A5 for lipoprotein hydrolysis!. J Clin Invest 115 (2005) 2694-2696
10. Vu-Dac N., Gervois P., Jakel H., et al. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J Biol Chem 278 (2003) 17982-17985
11. Talmud P.J., Hawe E., Martin S., et al. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet 11 (2002) 3039-3046
12. Pennacchio L.A., Olivier M., Hubacek J.A., et al. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet 11 (2002) 3031-3038
13. Lai C.Q., Tai E.S., Tan C.E., et al. The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore. J Lipid Res 44 (2003) 2365-2373
14. Lee K.W., Ayyobi A.F., Frohlich J.J., and Hill J.S. APOA5 gene polymorphism modulates levels of triglyceride. HDL cholesterol and FERHDL but is not a risk factor for coronary artery disease. Atherosclerosis 176 (2004) 165-172
15. Szalai C., Keszei M., Duba J., et al. Polymorphism in the promoter region of the apolipoprotein A5 gene is associated with an increased susceptibility for coronary artery disease. Atherosclerosis 173 1 (2004) 109-114
16. Talmud P.J., Martin S., Taskinen M.R., et al. APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study. J Lipid Res 45 (2004) 750-756
17. Lai C.Q., Demissie S., Cupples L.A., et al. Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham heart study. J Lipid Res 45 (2004) 2096-2105
18. Dallongeville J., Cottel D., Montaye M., et al. Impact of APOA5/A4/C3 genetic polymorphisms on lipid variables and cardiovascular disease risk in French men. Int J Cardiol 13 106 (2006) 152-156
19. Ruiz-Narvaez E.A., Yang Y., Nakanishi Y., Kirchdorfer J., and Campos H. APOC3/A5 haplotypes, lipid levels, and risk of myocardial infarction in the Central Valley of Costa Rica. J Lipid Res 46 (2005) 2605-2613
20. Wright W.T., Young I.S., Nicholls D.P., et al. SNPs at the APOA5 gene account for the strong association with hypertriglyceridaemia at the APOA5/A4/C3/A1 locus on chromosome 11q23 in the Northern Irish population. Atherosclerosis 185 (2006) 353-360
21. Bi N., Yan S.K., Li G.P., Yin Z.N., and Chen B.S. A single nucleotide polymorphism -1131 T > C in the apolipoprotein A5 gene is associated with an increased risk of coronary artery disease and alters triglyceride metabolism in Chinese. Mol Genet Metab 83 (2004) 280-286
22. Jong M.C., Hofker M.H., and Havekes L.M. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 19 (1999) 472-484
23. Li W.W., Dammerman M.M., Smith J.D., et al. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest 96 (1995) 2601-2605
24. Olivieri O., Stranieri C., Bassi A., et al. ApoC-III gene polymorphisms and risk of coronary artery disease. J Lipid Res 43 (2002) 1450-1457
25. Olivieri O., Bassi A., Stranieri C., et al. Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease. J Lipid Res 44 (2003) 2374-2381
26. Schaid D.J., Rowland C.M., Tines D.E., Jacobson R.M., and Poland G.A. Score tests for association of traits with haplotypes when linkage phase is ambiguous. Am J Hum Genet 70 (2002) 425-434
27. Storey J.D., and Tibshirani R. Statistical significance for genomewide studies. PNAS 100 (2003) 9440-9445
28. Sniderman A.D., Furberg C.D., Keech A., et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 361 (2003) 777-780
29. Sacks F.M., Alaupovic P., Moye L.A., et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) trial. Circulation 102 (2000) 1886-1892
30. Olivieri O., Martinelli N., Sandri M., et al. Apolipoprotein C-III, n - 3 polyunsaturated fatty acids, and "insulin-resistant" T-455C APOC3 gene polymorphism in heart disease patients: example of gene-diet interaction. Clin Chem 51 (2005) 360-367